Conference Coverage
Biogen’s aducanumab stumbles on cognitive endpoints at 6 mg/kg dose
Key clinical point: The antiamyloid antibody aducanumab failed to deliver cognitive benefits at 6 mg/kg, throwing some doubt on more positive...
The primary endpoint is change from baseline on the CDR-SB. Secondary endpoints are change on the MMSE, the Alzheimer’s Disease Assessment Study cognitive scale (ADAS-cog), and the Alzheimer’s Disease Cooperative Study activities of daily living and mild cognitive impairment scales (ADCS ADL, MCI). A subset of patients will undergo additional PET amyloid imaging as a tertiary endpoint.
Biogen is actively seeking patients for these studies. A recruitment website walks patients through some questions to identify those who might initially qualify.